[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627839":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":45,"collaborators":11,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":11,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":11,"enrollmentInfo":57,"targetDuration":11,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":11,"overallStatus":67,"whyStopped":11,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Chinese Academy of Medical Sciences, Fuwai Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"TEE Guided TAVR","EXPERIMENTAL",null,[13],"Procedure: TEE guided TAVR",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"PROCEDURE","TEE guided TAVR","TEE will be used to assess valve position and function, transvalvular gradients, paravalvular leak, and pericardial effusion, and to direct any adjunctive maneuvers (e.g., repositioning, post-dilation, or second-valve implantation) as clinically indicated.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Xiangbin Pan","CONTACT","+8688396666","panxiangbin@fuwaihospital.org",[27],{"facility":28,"status":11,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Fuwai Hospital","Beijing","Beijing Municipality","100037","China","CN",{"type":35,"coordinates":36},"Point",[37,38],116.39723,39.9075,{"lat":38,"lon":37},[41],{"name":42,"role":23,"phone":43,"phoneExt":11,"email":44},"Jie Dong","18311384217","jennidong97@icloud.com",{"type":46,"investigatorFullName":47,"investigatorTitle":28,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Pan Xiangbin","100627839","tavr-for-aortic-regurgitation-under-tee-guidance-100627839",false,"NCT07453849","TAVR for Aortic Regurgitation Under TEE Guidance","Radiation- and Contrast-Free TAVR for Aortic Regurgitation Under Transesophageal Echocardiography Guidance","Inclusion Criteria:\n\n* Age ≥18 years.\n* Severe native aortic regurgitation (AR) confirmed by echocardiography (per guideline-recommended multiparametric assessment).\n* Indication for intervention, defined as symptomatic severe AR (e.g., NYHA class II-IV) or asymptomatic severe AR with evidence of LV decompensation (e.g., reduced LVEF and\u002For LV dilation per guideline thresholds).\n* Deemed appropriate for transfemoral TAVR by a multidisciplinary Heart Team (e.g., elevated\u002Fprohibitive surgical risk or other clinical\u002Fanatomic factors favoring transcatheter therapy).\n\nExclusion Criteria:\n\n* Active infective endocarditis or ongoing systemic infection\u002Fsepsis.\n* Aortic pathology requiring open surgery, such as significant ascending aortic aneurysm\u002Froot disease above surgical thresholds, acute aortic syndrome, or other conditions where surgery is mandated.\n* Annulus\u002Flanding-zone dimensions outside device range","ALL","18 Years",{"count":58,"type":59},30,"ESTIMATED","INTERVENTIONAL",[62],"NA","Under contemporary practice, transcatheter aortic valve replacement (TAVR) is typically performed with fluoroscopic visualization and repeated injections of iodinated contrast. While effective, this paradigm introduces cumulative radiation exposure to both patients and staff and can be problematic in individuals with renal dysfunction, prior contrast reactions, or other situations where contrast use is undesirable. Treating native aortic regurgitation (AR) adds another layer of complexity: limited valvular\u002Fannular calcification, enlarged annular dimensions, and dynamic root motion may reduce frictional \"purchase\" and make prosthesis stabilization more demanding, thereby heightening the need for continuous, high-fidelity intraprocedural imaging. Transesophageal echocardiography (TEE), with its close acoustic window to the aortic root, provides detailed real-time information on annular geometry, cusp coaptation, LVOT-aortic root alignment, guidewire trajectory, and implant depth, and it allows immediate confirmation of valve function and rapid recognition of adverse events (e.g., significant paravalvular regurgitation, maldeployment, pericardial effusion, or coronary compromise). Leveraging TEE as the dominant imaging modality therefore represents a pragmatic pathway toward a low-radiation and potentially contrast-sparing-or in selected cases, contrast-free-TAVR workflow. Nevertheless, evidence supporting an \"echo-only\" TEE-guided approach remains sparse, especially for native AR. In this study, we present a standardized TEE-guided procedural protocol and report feasibility and early clinical outcomes of TEE-only TAVR in patients with aortic regurgitation.",[65,66],"Aortic Regurgitation","Transcatheter Aortic Valve Replacement","NOT_YET_RECRUITING","2026-03-02",{"date":70,"type":71},"2026-03-06","ACTUAL",{"date":73,"type":59},"2026-03-01",{"date":75,"type":59},"2026-12-31",{"name":5,"class":6},1]